% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@MISC{Mller:194998,
      author       = {Müller, Stephan A and Lichtenthaler, Stefan F},
      title        = {{D}ataset: {B}eneficial effect of {ACI}-24 vaccination on
                      microglial phenotypes in an amyloidosis mouse model},
      publisher    = {PRoteomics IDEntifications Database},
      reportid     = {DZNE-2023-00181},
      year         = {2023},
      abstract     = {Amyloid-beta (Aβ) deposition is an initiating factor in
                      Alzheimer´s disease (AD). Microglia are the brain immune
                      cells that surround and phagocytose Aβ, but their
                      phagocytic capacity declines in AD. This is in agreement
                      with studies that associate AD risk loci with genes
                      regulating phagocytic function. Immunotherapies are
                      currently pursued as therapeutic strategies against AD and
                      there are increased efforts to understand the role of the
                      immune system in ameliorating AD pathology. Here, we
                      evaluated the effect of the Aβ targeting ACI-24 vaccine in
                      preventing the AD pathology in an amyloidosis mouse model.
                      ACI-24 vaccination elicited a robust and sustained antibody
                      response in APPPS1 mice with an accompanying reduction of
                      Aβ plaque load, amyloid plaque-associated ApoE and
                      dystrophic neurites as compared to non-vaccinated controls.
                      Furthermore, plaque-associated microglia had the tendency to
                      be more activated post vaccination. The lower Aβ plaque
                      load triggered by vaccination with ACI-24 was in concordance
                      with the bulk transcriptomic analysis that revealed a
                      reduction in the expression of several disease-associated
                      microglial signatures. Accordingly, plaque-distant microglia
                      displayed a more ramified morphology, supporting beneficial
                      effects of the vaccination on bulk microglial phenotypes.
                      Our study demonstrates that administration of the Aβ
                      targeting vaccine, ACI-24, triggers protective microglial
                      responses that translate into a reduction of AD pathology
                      suggesting its use as a safe and cost effective AD
                      therapeutic intervention.},
      cin          = {AG Lichtenthaler},
      cid          = {I:(DE-2719)1110006},
      pnm          = {352 - Disease Mechanisms (POF4-352)},
      pid          = {G:(DE-HGF)POF4-352},
      typ          = {PUB:(DE-HGF)32},
      url          = {https://pub.dzne.de/record/194998},
}